Kalvista Pharmaceuticals Inc (KALV)

Nov 15, 2024

Insight into TANG CAPITAL MANAGEMENT LLC's Strategic Acquisition of KalVista Pharmaceuticals Inc Shares - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Suvretta Capital Management, LLC Increases Stake in KalVista Pha - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuti - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Capital World Investors Expands Stake in KalVista Pharmaceuticals - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Objective long/short (KALV) Report - Stock Traders Daily

Nov 13, 2024

Nov 12, 2024

KalVista Pharma (KALV) to Present at Stifel and Jefferies Healthcare Conferences | KALV Stock News - StockTitan

Nov 12, 2024

Nov 12, 2024

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Bakersfield Californian

Nov 12, 2024

Nov 07, 2024

Leerink Partnrs Has Bullish Estimate for KALV Q3 Earnings - MarketBeat

Nov 07, 2024

Nov 05, 2024

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline

Nov 05, 2024

Nov 05, 2024

Jones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN

Nov 05, 2024

Nov 05, 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace

Nov 05, 2024

Nov 05, 2024

KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance

Nov 05, 2024

Nov 05, 2024

KalVista prices $55M stock offering - MSN

Nov 05, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com

Nov 05, 2024

Nov 05, 2024

KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada

Nov 05, 2024

Nov 04, 2024

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com

Nov 04, 2024

Nov 04, 2024

U.S. Dollar/Moldova Lei (USDMDL) QuotePress Release - The Globe and Mail

Nov 04, 2024

Nov 04, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap UpHere's Why - MarketBeat

Nov 04, 2024

Nov 04, 2024

KalVista sets pricing for $60 million stock offering - Investing.com

Nov 04, 2024

Nov 04, 2024

DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart

Nov 04, 2024

Nov 04, 2024

Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail

Nov 04, 2024

Nov 04, 2024

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire

Nov 04, 2024

Nov 04, 2024

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - Yahoo Finance

Nov 04, 2024

Nov 03, 2024

KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com

Nov 03, 2024

Nov 03, 2024

Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat

Nov 03, 2024

Nov 02, 2024

(KALV) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Oct 30, 2024

Hereditary Angioedema Market Forecasted to Surge in Coming - openPR

Oct 30, 2024

Oct 28, 2024

sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 28, 2024

sebetralstat shows promise in phase 3 HAE trial - Investing.com India

Oct 28, 2024

Oct 28, 2024

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - The Bakersfield Californian

Oct 28, 2024

Oct 24, 2024

Hereditary Angioedema Market Size is Set for Rapid Growth as - openPR

Oct 24, 2024

Oct 22, 2024

(KALV) Trading Report - Stock Traders Daily

Oct 22, 2024

Oct 20, 2024

The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Oct 20, 2024

Oct 18, 2024

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Milton Daily Standard

Oct 18, 2024

Oct 16, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - MarketBeat

Oct 16, 2024

Oct 14, 2024

Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR

Oct 14, 2024

Oct 12, 2024

(KALV) Technical Data - Stock Traders Daily

Oct 12, 2024

Oct 10, 2024

Marshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat

Oct 10, 2024

Oct 09, 2024

Sweden Hereditary Angioedema Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024

Oct 09, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Decreased by Dimensional Fund Advisors LP - MarketBeat

Oct 09, 2024

Oct 08, 2024

Kalvista shares hold Buy rating, price target on HAE study By Investing.com - Investing.com South Africa

Oct 08, 2024

Oct 08, 2024

Kalvista shares hold Buy rating, price target on HAE study - Investing.com

Oct 08, 2024

Oct 07, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from HC Wainwright - MarketBeat

Oct 07, 2024

Oct 07, 2024

Kalvista asks 4 countries to OK sebetralstat as treatment for HAE - Angioedema News Today

Oct 07, 2024

Oct 05, 2024

KalVista Pharmaceuticals announces board election results - Investing.com India

Oct 05, 2024

Oct 04, 2024

KalVista Pharmaceuticals announces board election results By Investing.com - Investing.com Australia

Oct 04, 2024

Oct 04, 2024

Sebetralstat shows promise for anxiety in HAE attacks By Investing.com - Investing.com South Africa

Oct 04, 2024

Oct 04, 2024

Sebetralstat shows promise for anxiety in HAE attacks - Investing.com

Oct 04, 2024